Investornewsbreaks Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement To Acquire Italian Biotech Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI) , announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing P ...
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...
Avotres Inc. Founder And CSO, Dr. Hong Jiang Presented At The 7Th Treg-Directed Therapies Summit
Dr. Hong Jiang presented at 7th Treg-Directed Therapies Summit. BOSTON, MA, UNITED STATES, March 26, 2025 /EINPresswire / -- Avotres proudly a ...
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK ...
The Robesonian6d
Unraveling an oral health mystery leads to rare autoimmune diagnosis
Culton and Myers stressed the importance of raising awareness about these rare diseases and of getting more physicians and ...